APRE - CIK 0001781983
The table below shows Aprea Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | $23.90M | $37.88M |
| SG&A | $6.48M | $6.46M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $8.43M |
| $20.97M |
| $13.55M |
| $14.93M |
| Operating income | -$13.23M | -$14.32M | -$15.47M | -$113.39M | -$37.45M | - |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$12.60M | -$12.96M | -$14.29M | -$112.66M | -$37.13M | -$53.48M |
| EPS (diluted) | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 | -$50.61 |